ZP SPV 3 K/S: Financial statements 2022
CVR: 41038039
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ZP SPV 3 K/S (CVR 41038039) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 37,755,000 and a net result of DKK -1,791,000 compared with USD 50,000 the year before. That is an increase of 2,245% compared with the year before. The profit margin was -4.7%. Equity in the 2022 report amounted to DKK 35,174,000. The solvency ratio was 91.4%.
- Revenue
- DKK 37,755,000
- Gross Profit
- DKK 37,755,000
- Profit/Loss
- DKK -1,791,000
- Equity
- DKK 35,174,000
- Total Assets
- DKK 38,491,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 37.8M | 37.8M | -1.8M | 35.2M | - |
| 2021 | 1.6M USD | 1.6M USD | 50K USD | 5.6M USD | - |
| 2020 | 1K USD | 1K USD | -118 USD | 6K USD | - |
Official annual report
Keep an eye on ZP SPV 3 K/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ZP SPV 3 K/S has published its annual report for 2021. Revenue came to DKK 1,610,000, and the net result was DKK 50,000.
About ZP SPV 3 K/S
ZP SPV 3 K/S is a Danish company of the type Kommanditselskab based in Søborg, founded in 2019. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of ZP General Partner 3 ApS. The company is owned by ZEALAND PHARMA A/S. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,039,000 compared with DKK -34,739,000 the year before. Equity in the 2025 report amounted to DKK 429,000.
